What's Going On With NovoCure Stock Today?
Portfolio Pulse from Erica Kollmann
NovoCure Limited's (NASDAQ:NVCR) shares are trading higher after a loss of over 30% on Monday due to the failure of its phase 3 clinical trial of Tumor Treating Fields (TTFields) in patients with platinum-resistant ovarian cancer. Wells Fargo and HC Wainwright & Co. have revised their price targets for the company to $49 and $25 respectively.
August 29, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NovoCure's stock is recovering after a significant drop due to a failed clinical trial. Analysts have revised their price targets, indicating a potential decrease in the stock's value.
NovoCure's stock dropped significantly after the failure of a clinical trial, which is a major setback for the company. However, the stock is currently recovering. Analysts have revised their price targets, which could influence the stock's value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100